CDCO shares in $17 million funding
The Monash Institute of Pharmaceutical Sciences’ Centre for Drug Candidate Optimisation (CDCO) will put their share of $17 million funding towards the purchase of an Acoustic Ejection Mass Spectrometer.
Professor Susan Charman
The CDCO was one of four Monash University-led projects to share in $17 million from the Victorian Higher Education State Investment Fund (VHESIF) in 2022.
The funding will support the CDCO to purchase an Acoustic Ejection Mass Spectrometer – a state-of-the-art instrument designed to greatly expedite bioanalytical processing and increase throughput for pharmaceutical profiling of new drug candidates.
The Mass Spectrometer will enhance drug discovery by supporting medicinal chemistry, pharmaceutical optimisation and metabolomics/proteomics. These activities will strengthen the therapeutic pipeline in Victoria and Australia and accelerate the progression of new drug candidates toward clinical development.
“This significant contribution from the Victorian Government will help to purchase one of only two instruments in Australia with the ability to perform high-speed bioanalysis and the first to be applied to biopharmaceutical drug candidate optimisation in support of drug discovery,” said Professor Susan Charman, Director of the CDCO at MIPS.
“We are grateful to the Victorian Government and co-funders Therapeutic Innovation Australia (TIA) and the Monash University Platform Technology Research Network.”
The $350 million Victorian Higher Education State Investment Fund has been developed in response to the significant impact of the COVID-19 pandemic on Victorian universities. It aims to support them with capital works, applied research and research partnerships focused on boosting Victoria’s productivity and the economy.
